DENVER — In this video, Aaron M. Drucker, MD, ScM, FRCPC, FAAD, discusses some of the new molecules coming for atopic dermatitis that target OX40, IL-4 and IL-13 pathways, at the American Academy of Dermatology Annual Meeting.
According to Drucker, these molecules seem to have longer-acting effects, wider dosing intervals and efficacy that continues to improve past 16 weeks, beyond what current molecules provide.
“I’m excited to see how those stack up when we’re able to put them all into the same network meta-analysis in the next year or so, and we will continue to follow the field as things progress,” Drucker, head of dermatology at Sunnybrook Health Sciences Centre, dermatologist at Women’s College Hospital, senior scientist at Sunnybrook Research Institute and associate professor at the University of Toronto, told Healio.
Sources/Disclosures
Source:
Healio Interviews
Disclosures:
Drucker reports no relevant financial disclosures.
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
<
Leave a Reply